fbpx
Fighting Blindness Canada

Study Finds That Up to 30% of Patients with Wet AMD May be Able to Stop Anti-VEGF Injections

In a new study from Johns Hopkins University School of Medicine, almost a third of patients with wet age-related macular degeneration (AMD) were able to safely stop anti-VEGF (anti-vascular endothelial growth factor) injections, the most common treatment for wet AMD.

This study, published in the Journal of Clinical Investigation followed 106 people who each received a customized injection schedule. Patients were monitored at each visit to see if they could pause injections. Within one year, approximately 31% of patients had stopped treatment, with the majority of these patients remaining treatment-free for up to two years. Patients were considered to be safely weaned off anti-VEGF treatment if they
went at least 30 weeks without an injection, without having fluid accumulating in the eye or worsening vision loss.

The researchers also analyzed fluid from patient eyes and found 172 molecules that were different between those who safely stopped treatment compared to those who continued with monthly injections. The researchers will continue to study these molecules to try and identify biomarkers that may help predict which patients can stop treatment early.

The next step will be to perform a randomized trial to test if the same results are seen with a larger group of patients. If so, in the future it could give some patients the opportunity to safely pause or stop anti-VEGF injections while still maintaining eye health.

Featured Posts

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read More
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read More
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read More
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read More

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more

Canadian Optical Supply Announces Passing of Co-founder Judith Hochstadter

Judith Hochstadter, co-founder of Canadian Optical Supply (COS) together with her late husband, Fred, passed away Saturday, September 7, 2024.

Learn More
MIDO Square

MIDO | Milano Eyewear Show Announces New Dates for 2026 Edition

The trade show will take place January 31 to February 2 to avoid overlapping the Milano Cortina 2026 Winter Olympic Games.

Read more
Fighting Blindness Canada research

First Patients Treated in XLRP Gene Therapy Trial

Beacon Therapeutics, has announced that they have treated the first patients in their Phase 2/3 VISTA trial for a gene therapy for X-linked retinitis pigmentosa (XLRP).

Read more
CooperCompanies

CooperCompanies Recognized as a Best Workplace for Innovators

Leading global medical device company recognized for culture that drives innovation for customers and patients.

Read more
Nikon Optical Canada logo

Nikon Optical Unveils “Vision You Can Feel” Campaign in Canada

Nikon Optical Canada announces its launch of the 2024 brand campaign, Vision You Can Feel.

Read more